What is your preferred choice and timing of systemic therapy in a patient with high risk oligometastatic prostate cancer undergoing metastasis directed therapy to all sites of disease, including the prostate?
Answer from: Medical Oncologist at Academic Institution
Metastasis-directed therapy (MDT) is an option for patients with oligometastatic prostate cancer who wish to delay initiation of ADT, based on STOMP (Decaestecker et al., PMID: 25223986) and ORIOLE (Phillips et al., PMID: 32215577) trials. In the STOMP study, 61% of patients (3 or fewer metastases) ...
Comments
Radiation Oncologist at Providence St Mary Cancer Center Thank you for your summary of data regarding MDT. ...
Radiation Oncologist at NorthMain Radiation Oncology Do you offer elective pelvic RT as well?
Thank you for your summary of data regarding MDT. ...
Do you offer elective pelvic RT as well?